Skip to product information
1 of 4

Trilostane CAS13647-35-3

Trilostane CAS13647-35-3


Tralostam can inhibit 3 β- Dehydrogenase, which reduces the synthesis of cortisol and aldosterone, is clinically used in the treatment of Cushing's syndrome (hypercortisolemia) and primary Chemicalbook type hyperaldosteronism, but its efficacy in the treatment of Cushing's syndrome (hypercortisolemia) is not as effective as that of metolatone. This product also has a significant effect on reducing blood testosterone levels, which may be related to inhibiting its synthesis.

Mechanism of action

Breast cancer is a hormone dependent tumor, and estrogen is the main driver of the growth of this cancer cell. Therefore, one of the modern main therapies for breast cancer is to target estrogen, blocking the role of estrogen by inhibiting the production of estrogen or by blocking the estrogen receptor at its action site. Previously, estrogen receptors were thought to be only a single receptor, but recent studies have identified at least its presence α and β Two subtypes. Where estrogen binding α- Estrogen receptors can stimulate cell growth, but are associated with β- Estrogen receptor binding is downregulated α- Female Chemicalbook hormone receptors slow down the rate of cell proliferation. Studies have revealed that tralostam can not only reduce estrogen production, but also regulate the binding of estrogen to different subtypes of estrogen receptors α- Estrogen receptor inhibitors and β- The dual effects of estrogen receptor agonists ultimately block and alter the negative effects of estrogen on cancer cells. Tralostam's unique mode of action not only distinguishes it from other existing anti estrogen drugs, but also is the pharmacological basis for its highly effective treatment of breast cancer that fails to be treated by other anti estrogen therapies or is resistant to drugs.

Treatment of advanced breast cancer

Breast cancer is the most common tumor type in women. At present, for postmenopausal patients with hormone receptor positive or unknown type of breast cancer, clinical consensus recommends that anti estrogen drugs be the first choice for treatment, and the role of this therapy in delaying disease progression and improving survival time has long been affirmed and confirmed by a large number of studies. A new drug, Tralostam (trade name Modrenal), developed by biotech company BioEnvision, has been marketed for use in postmenopausal women with hormonal Chemicalbook selective cancer that has spread outside the breast. The drug can be used in two ways to slow down disease progression. For hormone sensitive breast cancer, estrogen promotes the growth of cancer cells by acting on two receptors, the estrogen receptor а Like cancer accelerators, estrogen receptors β Is the brake. Modrenal enhances the effect of estrogen on estrogen receptors β While weakening the absorption of estrogen receptors а The role of. It also acts on another site on the cell DNA, AP1, to reduce cell proliferation.
View full details

Get a Free Quote